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Abstract
Introduction:	The	nerve	sonographic	features	of	Dejerine-Sottas	disease	(DSD)	have	
not previously been described.
Methods:	This	exploratory	cross-	sectional,	matched,	case–control	study	investigated	
differences	 in	 nerve	 cross-	sectional	 area	 (CSA)	 in	 children	with	 DSD	 compared	 to	
healthy	controls	and	children	with	Charcot–Marie–Tooth	disease	type	1A	(CMT1A).	
CSA	of	the	median,	ulnar,	tibial,	and	sural	nerves	was	measured	by	peripheral	nerve	
ultrasound.	The	mean	difference	 in	CSA	between	children	with	DSD,	 controls,	 and	
CMT1A	was	determined	individually	and	within	each	group.
Results: Five children with DSD and five age- and sex- matched controls were enrolled. 
Data	from	five	age-	matched	children	with	CMT1A	was	also	included.	Group	compari-
son	showed	no	mean	difference	in	nerve	CSA	between	children	with	DSD	and	con-
trols. Individual analysis of each DSD patient with their matched control indicated an 
increase	in	nerve	CSA	in	three	of	the	five	children.	The	largest	increase	was	observed	
in a child with a heterozygous PMP22	point	mutation	(nerve	CSA	fivefold	larger	than	a	
control	and	twofold	larger	than	a	child	with	CMT1A).	Nerve	CSA	was	moderately	in-
creased in two children—one with a heterozygous mutation in MPZ and the other of 
unknown genetic etiology.
Conclusions:	Changes	in	nerve	CSA	on	ultrasonography	in	children	with	DSD	differ	
according	 to	 the	underlying	genetic	etiology,	confirming	 the	variation	 in	underlying	
pathobiologic processes and downstream morphological abnormalities of DSD sub-
types. Nerve ultrasound may assist in the clinical phenotyping of DSD and act as an 
adjunct to known distinctive clinical and neurophysiologic findings of DSD subtypes. 
Larger	studies	in	DSD	cohorts	are	required	to	confirm	these	findings.
K E Y W O R D S
Charcot–Marie–Tooth	disease,	Dejerine–Sottas	disease,	pediatric,	peripheral	neuropathy,	
ultrasound
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1  | INTRODUCTION
Dejerine–Sottas	 disease	 (DSD)	 comprises	 a	 genetically	 heteroge-
neous group of early- onset demyelinating hereditary neuropathies. 
The term was initially used to describe a clinical phenotype charac-
terized	by	symptom	onset	in	the	first	two	years	of	life,	delayed	motor	
development,	 hypotonia,	 and	 extremely	 slow	 nerve	 conduction	
(median	motor	nerve	conduction	velocity,	MNCV,	of	12	m/s	or	less;	
Gabreels-	Festen,	 2002;	 Ouvrier,	 McLeod,	 &	 Conchin,	 1987;	 Yiu	 &	
Ryan,	2012).	Other	common	clinical	features	include	areflexia,	mus-
cle	wasting	and	weakness,	 foot	deformity,	and	sometimes	enlarged	
nerves	on	clinical	examination	(Ouvrier	et	al.,	1987).	The	terminology	
used for the early- onset demyelinating neuropathies can be unclear. 
The clinical and neurophysiologic phenotype of DSD includes forms 
of	Charcot–Marie–Tooth	disease	 (CMT)	types	3	and	4	 (Yiu	&	Ryan,	
2012).	Dominant	de novo mutations in peripheral myelin protein 22 
(PMP22;	Roa,	Dyck,	Marks,	Chance,	&	Lupski,	1993),	myelin	protein	
zero	(MPZ;	Hayasaka	et	al.,	1993;	Warner	et	al.,	1998)	or	early	growth	
response	 2	 (EGR2)	 are	 the	most	 common	 causes	 of	 DSD.	 In	more	
than	50%	of	cases,	a	causative	genetic	mutation	cannot	be	identified	
(Baets	et	al.,	2011).
High-	resolution	peripheral	nerve	ultrasound	allows	rapid,	noninva-
sive	imaging	of	peripheral	nerves	(Goedee	et	al.,	2013).	Few	dedicated	
pediatric	 nerve	 ultrasound	 studies	 have	 been	 published.	 Yiu	 et	al.	
(2015)	found	a	two-	to	threefold	increase	in	nerve	cross-	sectional	area	
(CSA)	in	children	with	CMT1A	compared	to	controls.	Nerve	ultrasound	
may	play	a	 role	 in	 the	diagnosis	of	pediatric	 inherited	neuropathies,	
and	in	the	era	of	next-	generation	sequencing,	knowledge	of	specific	
nerve	 sonographic	 features,	 in	 addition	 to	 clinical	 and	neurophysio-
logic	findings,	may	assist	in	the	interpretation	of	genetic	testing	results.
We	evaluated	nerve	CSA	in	children	with	DSD	in	comparison	both	
with age- and sex- matched healthy controls and age- matched children 
with	CMT1A.
2  | MATERIALS AND METHODS
2.1 | Study objectives
The primary objective of this study was to investigate differences 
in	nerve	CSA	in	children	with	DSD	as	measured	by	peripheral	nerve	
ultrasound compared to healthy controls. Given the more severe 
clinical course and neurophysiologic abnormalities in DSD compared 
to	CMT1A,	we	hypothesized	 that	nerve	CSA	would	be	 significantly	
greater	in	children	with	DSD	compared	to	their	healthy	controls,	and	
greater	than	matched	children	with	CMT1A.	The	secondary	objective	
was to define the clinical features of DSD in this cohort.
2.2 | Study design and recruitment
This	 cross-	sectional,	 matched,	 case–control	 study	 was	 conducted	
at	 The	 Royal	 Children’s	 Hospital,	 Melbourne	 (RCH).	 Children	 with	
DSD were recruited from the neuromuscular clinic. Inclusion cri-
teria	 for	 children	with	DSD	 included	 (1)	 symptom	onset	 in	 the	 first	
2	years	of	life;	(2)	delayed	motor	development;	and	(3)	median	nerve	
MNCV	≤	12	m/s.	Healthy	controls	were	enrolled	at	a	ratio	of	1:1	and	
were	 age-	matched	 (within	 one	year	 either	 side)	 and	 sex-	matched.	
They were recruited from friends and family members of RCH staff 
and were screened for symptoms and signs of neuromuscular disor-
ders.	Data	from	matched	children	with	CMT1A	from	a	previous	study	
of	nerve	ultrasound	(Yiu	et	al.,	2015)	were	also	used	for	comparison.	
For	 children	with	CMT1A,	 age	match	 (within	1	year)	was	 chosen	 in	
preference to sex match.
2.3 | Nerve ultrasound
Nerve ultrasound images were obtained in the dominant upper and 
lower	limb	at	the	following	sites:	(1)	median	nerve	at	the	midhumerus	
(two-	thirds	from	the	lateral	tip	of	the	acromion	to	the	lateral	epicon-
dyle	of	the	humerus),	at	the	elbow	(in	the	cubital	fossa),	at	the	forearm	
(lower	third),	and	at	the	wrist	(at	the	level	of	the	lunate);	(2)	ulnar	nerve	
at	the	midhumerus,	just	distal	to	the	elbow	(one-	fifth	forearm	distance	
distal	to	the	medial	epicondyle),	and	at	the	midforearm;	(3)	tibial	nerve	
at	the	ankle;	and	(4)	sural	nerve	at	the	ankle.
All	 nerves	were	 transversely	 imaged	with	 the	 probe	 perpendic-
ular	 to	 the	 nerve,	 providing	 the	 most	 accurate	 and	 smallest	 CSA.	
Nerve	CSA	was	measured	by	tracing	the	nerve	just	inside	the	hyper-
echoic rim. Three images were taken and averaged at each nerve site. 
Ultrasound	 images	were	obtained	using	a	General	Electric	 (Fairfield,	
CT)	BT12	LOGIQ-	e	imaging	system	with	a	high-	frequency	(8–18	MHz)	
hockey	stick	transducer.	For	upper	limb	nerves,	participants	were	ex-
amined in the supine position with the arm supinated. For lower limb 
nerves,	participants	were	examined	in	the	left	or	right	lateral	position.	
The	ultrasonographer	(EY)	was	not	blinded	to	the	clinical	status	of	the	
participants.
2.4 | Clinical assessment
During	 the	 same	 study	 visit	 as	 the	 ultrasound	 assessment,	 weight	
and	height	were	recorded	and	body	mass	index	(BMI)	was	calculated.	
Children	with	DSD	also	underwent	a	neurologic	assessment,	 includ-
ing	history,	physical	examination,	and	assessment	using	the	Charcot–
Marie–Tooth	Pediatric	scale	(CMTPedS),	a	clinical	rating	tool	designed	
to	measure	disease	severity	in	children	with	CMT	(Burns	et	al.,	2012).	
This	11-	item	rating	tool	provides	a	total	score	between	0	and	44,	with	
a higher score reflecting greater impairment.
2.5 | Statistical analyses
Statistical analysis was performed using Stata statistical software 
13.0	 (Stata	Corp.	2013,	College	Station,	TX,	USA).	Demographics,	
body	metrics,	 and	clinical	 features	were	summarized	descriptively	
for all participants. Paired t tests were used to compare the mean 
difference	 in	 nerve	 CSA	 between	 children	 with	 DSD	 and	 their	
matched	 controls,	 and	 between	 matched	 children	 with	 CMT1A.	
Individual results were also plotted graphically. Sample size was 
convenience- based.
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2.6 | Standard protocol approvals, registrations, and 
patient consents
This	 study	was	 approved	 by	 the	 RCH	Human	 Research	 and	 Ethics	
Committee	 (HREC	number	34242).	 Informed	consent	was	obtained	
for all participants.
3  | RESULTS
Five	children	with	DSD	were	enrolled—one	boy	and	 four	girls,	with	
a	mean	 age	 of	 7.8	 (SD	 3.9)	years.	 Key	 clinical	 and	 genetic	 features	
are	shown	in	Table	1.	Case	5	has	been	previously	reported	(Yiu	et	al.,	
2017).	Five	age-	and	sex-	matched	controls	were	recruited	with	a	mean	
TABLE  1 Clinical	and	genetic	findings	in	five	children	with	Dejerine–Sottas	disease
Case number 1 2 3 4 5
Sex	(M/F) F M F F F
Age	at	visit	(years) 11.8 2.0 9.6 5.7 9.8
Gene mutation Unclassifieda EGR2	p.G356K	(htz) Unclassifiedb PMP22	p.S72L	
(htz)
MPZ	p.K130R	(htz)
Age	onset	(months) 6 At	birth 15 6 6
Presenting symptoms and signs
Motor delay Yes Yesc Yes Yes Yes
Hypotonia Yes Yes No Yes Yes
Hip	dysplasia	(bilateral) Yes No No No Yes
Reflexes Normal Reduced Normal Unknown Absent
Poor suck Yes Yes No No No
Neurophysiologic findings
Age	at	study 3	years,	8	months 7 months 3	years,	10	months 2	years,	2	months 1	year,	1	month
Median	nerve	MNCV	
(m/s)
3.0 4.1 9.1 Absent	response 12.0
Current symptoms and signs
Independently ambulant No No Yes No No
Wears	AFO’s Yes Yes No Yes Yes
Foot deformity Yesd Yesd No Yesd Yese
Hand weakness Yes Yes No Yes Yes
Bulbar dysfunction Yes Yes No Yes No
Reflexes Absent Absent Absent Absent Absent
Hip	flexion	(R/L)f 2+/3 NP 5/5 4+/4+ 2+/0
Ankle	dorsiflexion	(R/L)f 0/0 NP 5−/5− 4/4 3/3+
Shoulder	abduction	(R/L)f 4/4 NP 5/5 4/4 0/0
Hand	intrinsics	(R/L)f 2/2 NP 4+/4+ 4/4 0/0
CMTPedS	score	(0–44)g 42 NP 12 30 40
Complications
Respiratory insufficiency Yes Yes No No Yes
Scoliosis Yes Yes No Yes Yes
Hip	dysplasia	(bilateral) Yes No No Yes Yes
AFO,	ankle-	foot	orthoses;	CMTPedS,	Charcot–Marie–Tooth	disease	Pediatric	Scale;	htz,	heterozygous	mutation;	MNCV,	motor	nerve	conduction	velocity;	
NP,	not	performed.
aHeterozygous deletion of exons 4 and 5 of PMP22 detected with no mutation in other PMP22 allele.
bHeterozygous	p.Q203X	mutation	in	PRX	detected,	with	no	mutation	in	other	PRX allele.
cPresented at birth with hypotonia but also documented to have motor delay in first 2 years of life.
dPes planus.
eEquinovarus	foot	and	ankle	deformity.
fMRC	(Medical	Research	Council)	score.
gThe	CMTPedS	provides	a	total	score	between	0	and	44.	A	higher	score	reflects	greater	impairment.	The	scale	is	validated	for	children	>3	years	of	age.
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age	of	8.2	(SD	4.0)	years.	The	greatest	difference	in	age	between	each	
child	with	DSD	and	their	matched	control	was	9.8	months	(case	5—
control	9.8	months	older	than	DSD	case).	There	was	no	significant	dif-
ference	in	height,	weight,	or	body	mass	index	(BMI)	between	children	
with DSD and controls.
Clinical features of the five children with DSD are summarized 
in	 Table	1.	 The	mean	 age	 at	 onset	was	 6.6	 (SD	 5.4)	months.	All	
had delayed motor development. Four children presented with 
delayed	motor	 milestones,	 hypotonia,	 and/or	 hip	 dysplasia.	 The	
fifth	child	(case	2)	presented	at	birth	with	hypotonia,	hyporeflexia,	
aspiration,	and	feeding	problems	and	also	had	motor	delay	in	the	
first	 two	years	of	 life.	At	presentation,	 three	had	hyporeflexia	or	
areflexia.
At	the	time	of	the	study,	all	children	had	gait	abnormalities.	Four	
were	unable	to	walk	or	stand	independently,	wore	ankle-	foot	orthoses	
(AFO’s),	and	had	foot	deformity	and	weakness	of	the	hand	muscles.	
The	fifth	child	was	independently	ambulant	but	had	frequent	trips	and	
falls. Orthopedic complications were common—four children had sco-
liosis and three bilateral hip dysplasia. Three children had respiratory 
insufficiency,	with	reduced	vital	capacity	on	spirometry	and/or	recur-
rent	respiratory	infections	requiring	hospital	admissions.	One	child	re-
ceived	nocturnal	noninvasive	ventilation	(case	1).	Three	children	had	
bulbar dysfunction.
All	 children	 had	 distal	 lower	 limb	 muscle	 wasting—two	 mild,	
two	moderate,	 and	 one	with	 severe	wasting	 extending	 above	 the	
knee.	Wasting	of	the	thenar,	hypothenar,	and	intrinsic	hand	muscles	
was moderate in one child and severe in two. Weakness was most 
marked	distally;	 however,	most	 children	 also	had	proximal	muscle	
weakness of both upper and lower limbs. The CMTPedS scores 
reflect	the	overall	severity	of	the	neuropathy,	with	a	mean	of	31.0	
(SD	11.8).
3.1 | Neurophysiologic, neuropathologic, and 
genetic findings
Nerve conduction studies were performed in all children before 
four	years	of	age.	Median	nerve	MNCV	was	12	m/s	or	less	in	all	cases	
(Table	1).
One	child	(case	5)	had	a	sural	nerve	biopsy	at	15	months	of	age,	
which	showed	a	severe	depletion	of	large	diameter	myelinated	fibers,	
thinly	 myelinated	 intermediate	 diameter	 axons,	 and	 absent	 onion	
bulbs.	 Focal	 myelin	 folding	 was	 present	 on	 electron	 microscopy,	 a	
finding well described in MPZ-	related	neuropathies	(Yiu	et	al.,	2017).
Three	children	have	a	definitive	genetic	diagnosis,	with	mutations	
in	different	genes	 (Table	1).	Cases	4	and	5	have	previously	 reported	
pathogenic mutations in PMP22	(p.Ser72Leu)	and	MPZ	(p.Lys130Arg),	
respectively	 (Gabreels-	Festen	 et	al.,	 1996;	 Roa	 et	al.,	 1993).	 Case	 2	
has	a	novel	p.	Gly356Lys	de	novo	mutation	in	EGR2,	considered	likely	
to	be	pathogenic	[disease-	causing	on	in	silico	analysis,	low	frequency	
in	ExAC	(1/121266),	and	proximity	to	other	reported	mutations	p.As-
p355Val	and	p.Arg359Trp].	Case	3	had	a	relatively	mild	clinical	pheno-
type but marked conduction slowing. She is heterozygous for a novel 
nonsense mutation in PRX	(p.Gln203*);	a	second	mutation	in	this	gene	
or other genes associated with CMT has not been identified on whole- 
exome	sequencing.	Case	1	is	heterozygous	for	a	deletion	of	exons	4	
and 5 of PMP22	 in	 one	 allele,	without	 a	 demonstrable	mutation	 or	
copy	 number	 variant	 on	 the	 other	 allele,	 or	mutations	 in	 any	 other	
genes	 associated	with	CMT,	when	 tested	on	 a	 neuromuscular	 gene	
Nerve CSA, mm2
Measurement site DSD, mean (SD)
Controls, 
mean (SD)
Mean difference 
(95% CI) p- valuea
Median nerve at 
wrist
8.1	(3.6) 4.8	(0.6) 3.3	(−1.3,	7.9) .11
Median nerve at 
forearm
8.2	(4.5) 3.6	(0.8) 4.6	(−1.4,	10.6) .10
Median nerve at 
elbowb
10.9	(6.5) 4.3	(1.3) 6.6	(−12.2,	25.3) .27
Median nerve at 
midhumerusc
15.5	(2.5) 3.7	(0.4) 11.9	(−14.4,	38.1) .11
Ulnar	nerve	at	
forearm
6.3	(4.0) 2.9	(0.8) 3.4	(−2.2,	9.0) .17
Ulnar	nerve	at	
elbow
5.8	(3.2) 2.8	(0.8) 3.0	(−1.4,	7.4) .13
Ulnar	nerve	at	
midhumerusd
8.1	(4.3) 3.0	(0.7) 5.2	(−2.3,	12.6) .11
Tibial nerve at ankle 11.6	(5.5) 5.8	(0.9) 5.8	(−1.7,	13.3) .10
Sural nerve at ankled 1.9	(0.4) 1.4	(0.2) 0.5	(−0.4,	1.5) .18
CSA,	cross-	sectional	area;	SD,	standard	deviation;	CI,	confidence	interval.
ap- value from paired t test.
bData available on three children from each group.
cData available on two children from each group.
dData available on four children from each group.
TABLE  2 Nerve cross- sectional area in 
five	children	with	Dejerine–Sottas	disease	
compared to controls
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chip.	We	assume	there	may	be	another,	at	present,	unidentified	gene	
mutation contributing to her DSD phenotype. Coverage of the coding 
regions of PRX	(case	3)	and	PMP22	(case	1)	was	effectively	complete.
3.2 | Comparison of nerve CSA between children 
with DSD, healthy controls, and children with CMT1A
Whilst	nerve	CSA	was	greater	in	children	with	DSD,	there	was	no	
significant	 difference	 in	 nerve	 CSA	 between	 children	 with	 DSD	
and healthy controls at any site when analyzed using paired t tests 
(Table	2).	Due	 to	 the	genetic	heterogeneity	and	small	 size	of	 the	
cohort,	 nerve	CSA	was	 also	 individually	 compared	between	each	
child with DSD and their control. The difference in nerve size be-
tween children with DSD and controls differed markedly between 
participants.	Nerve	CSA	was	similar	 to	matched	controls	 in	cases	
1	 and	 2.	 Nerve	 CSA	was	markedly	 increased	 in	 cases	 4	 (PMP22 
point	mutation)	 and	5	 (MPZ	point	mutation)	 compared	 to	control	
values in all nerves studied. Case 3 showed variable increase in 
nerve	CSA	between	sites,	with	enlargement	seen	mainly	in	the	me-
dian	and	tibial	nerves	compared	to	the	matched	control	 (Figure	1	
and	Table	3).
An	additional	comparison	of	nerve	CSA	in	DSD	was	made	with	
age-	matched	children	with	CMT1A	from	a	previous	study	(Yiu	et	al.,	
2015).	There	was	less	than	7	months	difference	in	age	between	each	
child	with	DSD	and	their	matched	CMT1A	subject.	Three	children	
were not sex- matched. There was no significant difference between 
height	or	weight	between	children	with	DSD	and	CMT1A	(data	not	
shown).	 Figure	1	 and	 Table	3	 also	 show	 comparative	 nerve	 size	
in	 children	with	 CMT1A.	 Case	 4	 (PMP22	 point	mutation)	 demon-
strated	the	greatest	degree	of	nerve	enlargement,	with	nerve	CSA	
values approximately twice as large compared to a matched case 
of	CMT1A	and	five	times	as	 large	compared	to	a	matched	healthy	
control. Nerve size in cases 3 and 5 was enlarged to a similar degree 
to	that	seen	in	CMT1A.
4  | DISCUSSION
This single- center study confirms the genetic heterogeneity of the 
early-	onset	demyelinating	neuropathies	of	childhood,	 is	 the	first	 to	
describe the high- resolution nerve ultrasound features of this co-
hort	of	children,	and	demonstrates	a	marked	variability	in	the	degree	
of nerve enlargement in DSD. The latter likely reflects the genetic 
heterogeneity	 of	 DSD	 and	 subsequent	 downstream	 pathobiologic	
processes.
We	 previously	 showed	 a	 marked	 (two-	 to	 threefold)	 and	wide-
spread	increase	in	nerve	CSA	in	a	genetically	homogeneous	cohort	of	
children	with	CMT1A	(Yiu	et	al.,	2015).	The	present	study	sought	to	
compare	nerve	CSA	in	children	with	DSD	to	controls,	and	to	children	
with	CMT1A,	with	the	hypothesis	that	the	degree	of	nerve	enlarge-
ment	in	DSD	would	exceed	that	of	CMT1A,	given	its	generally	more	
severe clinical and neurophysiologic phenotype.
Our hypothesis was disproved; we found marked variability in the 
degree of nerve enlargement in children with DSD compared to age- 
and gender- matched healthy controls. Case 4 was the only subject in 
our cohort with findings in keeping with our original hypothesis. She 
demonstrated	the	greatest	increase	in	nerve	CSA—four	to	five	times	
greater than her matched control and approximately twice that of an 
age-	matched	child	with	CMT1A.	Interestingly,	she	is	heterozygous	for	
a point mutation in PMP22,	the	same	gene	duplicated	in	CMT1A.
Two other children demonstrated significant nerve enlargement. 
The	 first,	 a	 child	 with	 a	 heterozygous	 point	 mutation	 in	MPZ had 
F IGURE  1 Nerve	CSA	in	children	with	DSD	compared	to	matched	controls	and	children	with	CMT1A.	Nerve	CSA	at	three	sites	shown	for	
each	child	with	DSD	compared	to	their	matched	control	and	CMT1A	case.	Each	stacked	column	shows	nerve	CSA	for	the	median	nerve	at	
the	forearm	(shaded	black	with	white	spots),	ulnar	nerve	at	the	forearm	(black	and	white	stripes),	and	tibial	nerve	at	the	ankle	(black	and	white	
diamonds).	CMT1A,	Charcot–Marie–Tooth	disease	type	1A;	CSA,	cross-	sectional	area;	DSD,	Dejerine–Sottas	disease
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Nerve Site Case
Nerve CSA (mm2)
DSD Control CMT1A
Median nerve Wrist 1 5.9 5.4 8.8
2 3.9 4.0 5.1
3 8.5 4.9 9.6
4 13.3 4.2 8.2
5 8.8 5.3 7.5
Forearm 1 4.6 4.3 17.3
2 3.9 2.8 5.1
3 9.0 4.1 10.0
4 15.1 2.6 6.4
5 8.6 4.1 9.0
Elbow 1 4.7 4.8 NP
2 NP 3.5 NP
3 7.0 NP NP
4 17.7 2.9 NP
5 10.3 5.3 NP
Midhumerus 1 NP 5.0 NP
2 NP 4.1 NP
3 10.8 NP NP
4 17.3 3.4 NP
5 13.8 4.0 NP
Ulnar	nerve Forearm 1 3.2 3.3 20.0
2 3.5 2.2 4.6
3 5.1 3.5 9.6
4 13.1 1.8 5.7
5 6.4 3.7 9.4
Elbow 1 3.8 3.0 12.6
2 3.1 2.1 4.6
3 4.3 3.9 12.3
4 10.8 2.0 4.5
5 7.1 3.2 8.6
Midhumerus 1 5.2 3.9 NP
2 3.7 2.7 NP
3 4.8 NP NP
4 12.5 2.2 NP
5 11.1 3.0 NP
Tibial nerve Ankle 1 9.2 5.8 17.9
2 5.2 5.6 7.2
3 11.2 6.8 17.0
4 20.2 4.4 11.4
5 12.4 6.5 10.3
Sural nerve Ankle 1 1.6 1.6 4.6
2 NP 1.2 NP
3 1.6 1.2 2.4
4 2.5 1.1 1.7
5 1.8 1.5 5.1
CMT1A,	 Charcot–Marie–Tooth	 disease	 type	 1A;	 CSA,	 cross-	sectional	 area;	 DSD,	 Dejerine–Sottas	
	disease;	NP,	not	performed.
TABLE  3 Nerve cross- sectional area in 
children with DSD compared to matched 
controls	and	children	with	CMT1A
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nerve	CSA	approximately	double	that	of	her	matched	healthy	control.	
The	second	child	(case	3)	showed	variable	nerve	enlargement	at	dif-
ferent sites. It is not clear if this finding represents true variability in 
nerve enlargement in this case or sampling error. The genetic etiology 
of	this	case	remains	unclear,	as	a	second	mutation	has	not	been	found	
in the PRX gene. The 2- year- old boy with an EGR2 mutation showed 
minimal	 to	 no	nerve	 enlargement,	 and	 the	 remaining	 child	 (case	1)	
showed	no	 increase	 in	 nerve	CSA.	The	 genetic	 cause	 of	 this	 latter	
case is unclear. She has a single exonic deletion in one PMP22 allele 
but no identifiable mutation in the other allele. This is not thought 
to explain her clinical phenotype—heterozygous PMP22 deletions are 
usually	associated	with	hereditary	liability	to	pressure	palsies,	whilst	
children with early- onset demyelinating neuropathies usually have 
compound heterozygous deletions of PMP22	 (Abe	 et	al.,	 2010;	Al-	
Thihli	et	al.,	2008).	Given	the	lack	of	nerve	enlargement	in	this	case	
compared to the child with a PMP22	point	mutation,	one	could	hy-
pothesize	that	this	child	either	has	a	mutation	in	another	gene	or,	if	
she	does	have	a	second,	as	yet	undetected	mutation	in	PMP22,	that	
this reflects mutation- specific effects of different PMP22 mutations 
on nerve enlargement.
The	 increase	 in	 nerve	 CSA	 seen	 on	 nerve	 ultrasound	 parallels	
the	increase	in	total	transverse	fascicular	area	(TTFA)	seen	in	neuro-
pathologic	studies	of	CMT.	In	CMT1A,	TTFA	is	1.5-	to	twofold	that	
of	healthy	controls	 (Gabreels-	Festen,	2002),	 reflecting	 the	 increase	
in	nerve	CSA	seen	by	nerve	ultrasound	 (Yiu	et	al.,	2015).	Similarly,	
Gabreels–Festen	documented	a	TTFA/normal	 ratio	of	393%–458%	
in children with PMP22	 missense	 mutations	 and	 a	 92%–276%	 in	
individuals with MPZ	 missense	 mutations;	 Gabreels-	Festen	 (2002)	
findings	in	keeping	with	the	changes	seen	in	nerve	CSA	in	the	pres-
ent	 study.	The	marked	 increase	 in	TTFA	 is	 thought	 to	 be	 second-
ary to an increase in collagen fibers and endoneurial extracellular 
matrix	 (Gabreels-	Festen,	 2002;	Yiu	 et	al.,	 2015).	 Large	 numbers	 of	
onion bulbs may also contribute to increased fascicular size in DSD. 
Unfortunately,	there	is	little	published	data	on	TTFA	or	endoneurial	
collagen in patients with EGR2 or PRX mutations. Only one child in 
this	study	(with	an	MPZ	mutation)	had	a	nerve	biopsy	performed.	This	
biopsy	showed	a	severe	reduction	 in	myelinated	fibers,	 thin	myelin	
sheaths,	 and	 an	 absence	 of	 onion	 bulbs;	 features	 not	 expected	 to	
cause	significant	nerve	enlargement.	Unfortunately,	TTFA	and	endo-
neurial	collagen	content	were	not	reported.	This,	along	with	the	fact	
that	the	biopsy	was	performed	at	15	months	of	age,	8	years	prior	to	
the	nerve	ultrasound,	makes	neuropathologic	and	sonographic	cor-
relations difficult.
The variable nerve ultrasound findings in this study reflect 
the	genetic	heterogeneity	of	DSD,	confirming	that	the	underlying	
pathobiologic processes and downstream morphological abnormal-
ities vary between DSD subtypes. This has been demonstrated at 
a neuropathologic level—where findings such as loss of myelinated 
fibers,	 reduced	myelin	 thickness,	 and	 a	marked	 increase	 in	 onion	
bulb	 formations	 are	 common	 to	 all	 forms	 of	DSD,	 but	 additional	
pathological	 findings,	 such	as	 focal	myelin	 folding,	 are	associated	
with specific genetic subtypes. If we postulate that the main con-
tributor to nerve enlargement is increased volume of endoneurial 
extracellular	matrix	 and	 perhaps	 onion	 bulb	 formations,	 the	vari-
able nerve ultrasound findings in this study may reflect the effect 
of different gene mutations on extracellular matrix production and 
onion	bulb	formation,	either	directly	or	via	abnormal	Schwann	cell-	
extracellular	matrix	 interplay	 (Colognato	&	Tzvetanova,	2011;	Yiu	
et	al.,	2015).
In	CMT1A,	nerve	CSA	shows	a	modest	correlation	with	disability	
(Yiu	et	al.,	2015).	Although	limited	by	the	small	sample	size,	the	degree	
of nerve enlargement did not appear to correlate with clinical severity 
in	this	study,	as	measured	by	the	CMTPedS	total	score.	Four	children	
had marked neurologic disability; three of the four children old enough 
to	perform	the	CMTPedS	had	scores	greater	than	30,	indicating	severe	
impairment.
This study has a number of limitations. Due to low prevalence of 
DSD,	the	sample	size	was	small,	limiting	statistical	analysis.	The	ultra-
sonographer was not blinded to the clinical status of the patient.
The workup of early- onset neuropathies involves clinical history 
and	examination,	neurophysiologic	 studies,	 and	genetic	 testing.	 In	
the	era	of	next-	generation	sequencing,	specific	nerve	sonographic	
features may act as an adjunct to clinical and neurophysiologic phe-
notyping	of	DSD,	and	hence,	interpretation	of	genetic	testing	results	
particularly in the interpretation of variants of unknown significance. 
The rapid and noninvasive nature of nerve ultrasound makes it an 
attractive	imaging	technique	in	children,	complementing	neurophys-
iologic	testing.	Studies	in	larger	DSD	cohorts,	especially	those	with	
similar	genetic	etiology,	are	required	to	confirm	the	findings	of	the	
current study and determine whether nerve ultrasound can accu-
rately	differentiate	between	different	genetic	causes	of	DSD.	Larger	
cohorts may show correlation with disease severity in genetically 
homogeneous	cohorts	of	patients.	Longitudinal	studies	will	provide	
insight into the responsiveness of nerve ultrasound to change over 
time,	and	its	value	as	a	biomarker	in	natural	history	studies	and	trials	
of future therapies.
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